Rethinking the Platinum Standard in SCLC: A Meta-Analysis of Limited- and Extensive-Stage Disease in the Immunotherapy Era.
This study evaluated the impact of platinum backbone selection on survival outcomes across the SCLC spectrum in the immunotherapy era. Prioritizing carboplatin as a preferred agent may optimize tolerability while preserving or improving survival outcomes across the SCLC spectrum.
This study evaluated the impact of platinum backbone selection on survival outcomes across the SCLC spectrum in the immunotherapy era. Prioritizing carboplatin as a preferred agent may optimize tolerability while preserving or improving survival outcomes across the SCLC spectrum.
What the study was
- Study design
- Randomized controlled trial
- Population
- Human participants; details are provided in the abstract.
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- JTO clinical and research reports
Why it surfaced
Retained as a 8/10 high-priority candidate for Novel therapeutics: immunotherapy, CAR-T, targeted therapy; PubMed metadata and abstract were assessed conservatively.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.